Mr. Roy will bring exceptional financial expertise to PharmAla's Board and improve the company's corporate governance
VANCOUVER, BC, July 4, 2022 /CNW/ - PharmAla Biotech Holdings Inc. (CNSX: MDMA) is pleased to announce that it has appointed Mr. Kevin Roy to its board of directors. An exceptionally qualified former CFO, Mr. Roy will lend his financial expertise to the company.
"I'm so pleased to welcome Kevin to the PharmAla Board. He brings exactly the kind of experience we need to our team," said Jodi Butts, PharmAla's Board Chair. "His strong accountancy and fiduciary experience will increase the company's corporate governance and allow us to continue growing the business of supporting clinical trial practitioners globally."
Mr. Roy is a former executive team member at FirstService Corporation (FSV: TSX, NASDAQ), having served as CFO of FirstService Brands division, and is a Chartered Professional Accountant. He lives in Toronto with his family. Mr. Roy will serve as chair of the Company's Audit Committee.
"I'm excited to join PharmAla's board and contribute to the company's growth," said Kevin Roy. "The company's development over the past year has been impressive, and I am fully committed to the company's mission of developing MDMA as a treatment for a number of mental health conditions."
PharmAla Biotech also announces, with gratitude and regret, the resignation of former Director Solomon Elimimian.
For more information, please visit www.PharmAla.ca, where you can sign up to receive regular news updates.
PharmAla Biotech Holdings Inc. (CSE: MDMA) is a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules, including MDMA. PharmAla was founded with a dual focus: alleviating the global backlog of generic, clinical-grade MDMA to enable clinical trials, and to develop novel drugs in the same class. PharmAla is a “regulatory first” organization, formed under the principle that true success in the psychedelics industry will only be achieved through excellent relationships with regulators. Our team of dedicated professionals includes regulatory experts, scientists, and biomanufacturing professionals. PharmAla has built what it believes to be North America’s first cGMP MDMA value chain, encompassing GMP manufacturing of Active Pharmaceutical Ingredient (API), and drug product formulation. PharmAla’s research and development unit has also begun preclinical research into two patented Novel Chemical Entities (NCEs) based on MDXX class molecules, with proof-of-concept research currently ongoing at the University of Arkansas Medical School.
Nicholas Kadysh, CEO
press@pharmala.ca